Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
CLGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.56 - $6.75
Previous CloseN/A
Volume800.00
Average Volume (3M)9.65K
Market Cap
$30.35M
Enterprise Value$32.16M
Total Cash (Recent Filing)$5.33M
Total Debt (Recent Filing)$44.61K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
May 22, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding11,454,512
10 Day Avg. Volume20,653
30 Day Avg. Volume9,647
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$11.00Price Target Upside315.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Collplant Holdings News
PremiumCompany Announcements
CollPlant Biotechnologies Reports 2024 Financial Results
PremiumCompany Announcements
CollPlant’s Earnings Call: Mixed Outlook Amid Innovations
PremiumPre-Earnings
Is CLGN a Buy, Before Earnings?
PremiumCompany Announcements
CollPlant Expands VergenixSTR Distribution Across Europe and Asia
---
Bulls Say, Bears Say
Bulls Say
PartnershipsCollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.
Product DevelopmentEncouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.
Bears Say
Financial PerformanceThe company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
12.14% Other Institutional Investors
87.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CLGN FAQ
What was Collplant Holdings’s price range in the past 12 months?
Collplant Holdings lowest stock price was $2.56 and its highest was $6.75 in the past 12 months.
What is Collplant Holdings’s market cap?
Collplant Holdings’s market cap is $30.35M.
When is Collplant Holdings’s upcoming earnings report date?
Collplant Holdings’s upcoming earnings report date is May 22, 2025 which is in 54 days.
How were Collplant Holdings’s earnings last quarter?
Collplant Holdings released its earnings results on Mar 26, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.2.
Is Collplant Holdings overvalued?
According to Wall Street analysts Collplant Holdings’s price is currently Undervalued.
Does Collplant Holdings pay dividends?
Collplant Holdings does not currently pay dividends.
What is Collplant Holdings’s EPS estimate?
Collplant Holdings’s EPS estimate is -0.04.
How many shares outstanding does Collplant Holdings have?
Collplant Holdings has 11,454,512 shares outstanding.
What happened to Collplant Holdings’s price movement after its last earnings report?
Collplant Holdings reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Collplant Holdings?
Currently, no hedge funds are holding shares in CLGN
---
Collplant Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (315.09% Upside)
$11.00 (315.09% Upside)
Hedge Fund Trend
Decreased
By 235.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.33%
12-Months-Change
Fundamentals
Return on Equity
-79.46%
Trailing 12-Months
Asset Growth
-45.17%
Trailing 12-Months
Company Description
Collplant Holdings
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
---
CLGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Read More>---
CLGN Stock 12 Month Forecast
Average Price Target
$11.00
▲(315.09% Upside)
Technical Analysis
Best Analysts Covering CLGN
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-2.73%
initiated a buy rating 8 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -2.73% per trade.
---